In the medtech market, SVB predicts that late-stage investment will continue to slow and major firms will push back going public until at least late 2023 because of market pressures, according to a Jan. 6 SVB news release.
“Looking ahead to 2023, while there is still uncertainty in the private investment landscape, the strongest companies will get funded,” SVB Managing Director Jonathan Norris said.
